Navigation Links
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients


WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.

Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.

Isentress is expected to launch during the fourth quarter of 2007, according to Merck.

Dr. Eash can provide:

-- Insight on the class of integrase inhibitors and particularly Isentress

and its potential effect on other drugs in the HIV market.

-- Key factors that will have an impact on Isentress's uptake and use. How

will Isentress be positioned in the lines of HIV treatment?

-- The main drivers and barriers for its use. What is the forecast for

Isentress? Which drugs will be its main competition?

-- Key thought leaders' perceptions about Isentress.

-- Isentress's impact on the HIV market and on the overall HIV therapeutic


Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from Brown University. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.

To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Erica Ames


SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A Vaccine for the impending pandemic Avian Influenza
2. India warned of Impending AIDS Disaster
3. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
4. Now, Cellphones That Alert Against Impending Lightning Strikes
5. WHO Gives Its Approval For Bird Flu Test Kit
6. Ranbaxy gets US FDA approval for Lisinopril
7. Approval for DNA test to detect cystic fibrosis
8. Aurobindo gets U.S. FDA approval for Cephalexin
9. Cadila gets US FDA approval for Promethazine tablets
10. Vaccine For Cervical Cancer Awaits Approval
11. Anti-obesity drugs for FDA approval
Post Your Comments:
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... For the ... companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two groups ... to aid in MAP International’s cause. , MAP International was founded in 1954 and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, the industry ... Wimbledon Athletics Facebook page to educate the public, parents and school athletic ... 2,000 people under the age of 25 die from sudden cardiac arrest every ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... , Nov. 25, 2015  Henry Schein, Inc., ... services to office-based dental, medical and animal health practitioners, ... Meeting the Henry Schein ConnectDental® Pavilion , which ... array of open solutions designed to help any practice ... Click here for a schedule of experts appearing ...
Breaking Medicine Technology: